Hepatitis B treatment: Lessons for the nephrologist

Kidney International

Volumn 70, Issue 11, 2006, Pages 1897-1904

  Olsen, S K ^a,b   Brown Jr , R S ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Anti viral therapy; Cirrhosis; Hemodialysis; Hepatitis B; Renal transplant; Vaccine

Indexed keywords

BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BODY FLUID; DISEASE EXACERBATION; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; INFECTION COMPLICATION; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MEDICAL SPECIALIST; NEPHROLOGY; PRIORITY JOURNAL; SHORT SURVEY; VIRUS TRANSMISSION;

ALGORITHMS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; VACCINATION;

EID: 33845252959     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001908     Document Type: Short Survey

References (51)

1. Pawlotsky J-M. Virology of hepatitis B and C viruses and antiviral agents. J Hepatol 2006; 44: S10-S13.
2. Ganem D, Prince A. Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
3. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15: 162-171.
4. Minuk G, Dong S, Rebecca G et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40: 1072-1077.
5. Brechot C, Thiers V, Kremsdorf D et al. Persistent hepatitis B virus: clinically significant or purely occult? Hepatology 2001; 34: 194-203.
6. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495.
7. Aroldi A, Lampertico P, Montagnino G et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136.
8. Fabrizi F, Martin P, Dixit V et al. HbsAgbSeropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transpl 2005; 5: 2913-2921.
9. Rajendra B, Mohamed CH. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198-211.
10. Cadrobbi P, Bortolotti F, Zacchello G et al. Hepatitis B virus replication in acute glomerulonephritis with chronic active hepatitis. Arch Dis Child 1985; 60: 583-585.
11. Lau GKK, Teerha P, Luo LK et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
12. Marcellin P, Lau G, Bonino F et al. Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
13. Rostaing L, Modesto A, Baron E et al. Acute renal failure in kidney transplant patients treated with interferon alfa 2b for chronic hepatitis C. Nephron 1996; 74: 512-516.
14. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1991; 47: 225-230.
15. Rostaing L, Henry S, Cisterne JM et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627.
16. Kletzmayr J, Watschinger B, Muller C et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant patients. Transplantation 2000; 70: 1404-1407.
17. Kamar N, Sandres-Saune K, Ribes D et al. Effects of long term Lamivudine therapy in renal-transplant patients. J Clin Virol 2004; 31: 298-303.
18. Leung LW, Lai CL, Chang TT et al. Extended Lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532.
19. Guan R, Lai CL, Liaw YF et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic Hepatitis B (abstract). J Gastroenterol Hepatol 2001; 16: A60.
20. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long term lamivudine monotherapy in patients with E antigen negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
21. Fontana RJ, Hann HW, Wright T et al. A multi-center study of Lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-510.
22. Tang S, Lai F, Lui Y et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-1758.
23. Chan TK, Tse KC, Tang C et al. Prospective study on Lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transpl 2004; 4: 1103-1109.
24. Han DJ, Kim TH, Park SK et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg(+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71: 387-394.
25. Chan TM, Fang GX, Tang C et al. Preemptive lamivudine therapy based on HBV DNA Level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.
26. Benhamou Y, Thibault V, Vig P. Long term treatment with adefovir dipivoxil 10mg in patients with lamivudine resistant HBV and HIV Co-infection results in significant and sustained clinical improvement. 15th International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. Abstract WeOrA 1329.
27. Herreros de Tejada Echanojauregui A, Moreno Planas JM, Rubio Gonzalez E et al. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transpl Proc 2005; 37: 1507-1508.
28. Marcellin P, Chang T-T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
29. Schiff E, Perillo R, Hann H-W et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
30. Peters M, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
31. Hadziyannis SJ, Tassopoulos N, Heathcote J et al. Long-term therapy with adefovir dipivoxil for HBeAg- negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-2681.
32. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovi dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 673-681.
33. Izzedine H, Hulot JS, Launay-Vacher V et al. Adefovir dipivoxil international 437 study group. renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-1158.
34. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir in kidney recipients. hemodialysis patients. and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092.
35. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior in reducing HBV DNA in patients with chronic Hepatitis B infection. Gastroenterology 2002; 123: 1831-1838.
36. Chang TT, Gish R, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
37. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
38. Lau G, Cooksley H, Ribeiro RM et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg(+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology 2004; 40(Suppl 1): 272A.
39. Chien-Jen C, Hwai-I Y, Jun S et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 29: 565-573.
40. Werle B, Wursthorn K, Petersen J et al. Quantitative analysis of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivolxil therapy: an international multicenter study (abstract). Hepatology 2002; 36(Suppl 4): 296A.
41. Poussin K, Diennes H, Sirma H et al. Expression of mutated hepatitis B virus X gene in human hepatocellular carcinomas. Int J Cancer 1999; 80: 497-505.
42. Brechot C, Theirs V, Kremsdorf D et al. Persistent hepatitis B virus infection in subjects without hepatitis surface antigen: clinically significant of purely 'occult'? Hepatology 2001; 34: 194-203.
43. Keefe EB, Dieterich DT, Steve-Huy H et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepato 2004; 2: 87-106.
44. Fabrizi F, Lunghi G, Finazzi S et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009-1015.
45. Fabrizi F, Di Filippo S, Marcellin D et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72: 536-543.
46. Vlassopoulos D. Recombinant hepatitis B vaccination in renal failure patients. Curr Pharm Biotechnol 2003; 4: 141-151.
47. DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 6: 1184-1192.
48. Sennesael JJ, van der Niepen P, Verbeelen DL. Treatment with recombinant erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121-128.
49. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Org 2002; 26: 492-496.
50. Mat O, Mestrez F, Beauwens R et al. Primary high-dose intradermal hepatitis B vaccination in hemodialysis: cost-effectiveness evaluation at 2 years. Hemodial Int 2006; 10: 49-55.
51. Chiew TNK, Jiri B, Ann KS et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303.